JAMA Cardiology

JAMA Cardiology JAMA Cardiology is a member of the JAMA Network, a consortium of peer-reviewed publications

FINEARTS-HF: Finerenone reduced the risk of total worsening HF events and cardiovascular death, and it improved symptoms...
09/02/2025

FINEARTS-HF: Finerenone reduced the risk of total worsening HF events and cardiovascular death, and it improved symptoms. https://ja.ma/3Jdtxpg

From JAMA: Among patients with acute myocardial infarction, routine screening for Helicobacter pylori did not significan...
09/01/2025

From JAMA: Among patients with acute myocardial infarction, routine screening for Helicobacter pylori did not significantly reduce upper gastrointestinal bleeding.



https://ja.ma/422H8WV

In this secondary analysis of the AZALEA-TIMI 71 RCT, abelacimab consistently reduced the risk of bleeding relative to r...
09/01/2025

In this secondary analysis of the AZALEA-TIMI 71 RCT, abelacimab consistently reduced the risk of bleeding relative to rivaroxaban irrespective of kidney function.



https://ja.ma/3HVEyv7

From JAMA: Among patients with acute myocardial infarction, routine screening for Helicobacter pylori did not significan...
09/01/2025

From JAMA: Among patients with acute myocardial infarction, routine screening for Helicobacter pylori did not significantly reduce upper gastrointestinal bleeding.



https://ja.ma/4my9Sz4

From JAMA: Among patients with NSTEMI and multivessel disease, FFR-guided complete revascularization reduced the risk of...
08/31/2025

From JAMA: Among patients with NSTEMI and multivessel disease, FFR-guided complete revascularization reduced the risk of death, nonfatal myocardial infarction, revascularization, and stroke at 1 year compared with culprit-only revascularization.



https://ja.ma/3VqYtoM

JAMA Editorial: Discontinuing anticoagulation therapy after AF ablation may be beneficial for patients at intermediate s...
08/31/2025

JAMA Editorial: Discontinuing anticoagulation therapy after AF ablation may be beneficial for patients at intermediate stroke risk and high bleeding risk, although careful monitoring and shared decision-making are essential.



https://ja.ma/4gaO9eb

From JAMA: In patients without atrial arrhythmia recurrence after AF ablation, discontinuing oral anticoagulant therapy ...
08/31/2025

From JAMA: In patients without atrial arrhythmia recurrence after AF ablation, discontinuing oral anticoagulant therapy reduced the composite risk of stroke, systemic embolism, and major bleeding compared with continued therapy.



https://ja.ma/47f2u70

From JAMA Network Open: Despite advances in trial design, women are underrepresented in cardiovascular research, especia...
08/31/2025

From JAMA Network Open: Despite advances in trial design, women are underrepresented in cardiovascular research, especially for high-risk conditions like arrhythmias, coronary heart disease, and acute coronary syndrome.



https://ja.ma/3I1vZPn

From JAMA: In patients with cardiometabolic , and reduced the risk of hospitalization for heart failure or all-caus...
08/31/2025

From JAMA: In patients with cardiometabolic , and reduced the risk of hospitalization for heart failure or all-cause mortality compared to sitagliptin, but tirzepatide offered no additional benefit over semaglutide.



https://ja.ma/3JDRBBU

A man in his early 50s presented with recurrent episodes of cough, palpitations, shortness of breath, and exertional che...
08/31/2025

A man in his early 50s presented with recurrent episodes of cough, palpitations, shortness of breath, and exertional chest pain.

What would you do next? https://ja.ma/45R9VAl

From JAMA Network Open: Despite advances in trial design, women are underrepresented in cardiovascular research, especia...
08/31/2025

From JAMA Network Open: Despite advances in trial design, women are underrepresented in cardiovascular research, especially for high-risk conditions like arrhythmias, coronary heart disease, and acute coronary syndrome.



https://ja.ma/4mHxT6Z

From JAMA: In patients with cardiometabolic , and reduced the risk of hospitalization for heart failure or all-caus...
08/31/2025

From JAMA: In patients with cardiometabolic , and reduced the risk of hospitalization for heart failure or all-cause mortality compared to sitagliptin, but tirzepatide offered no additional benefit over semaglutide.



https://ja.ma/47kircb

Address

330 N Wabash Avenue
Chicago, IL
60611

Telephone

+13126707827

Website

Alerts

Be the first to know and let us send you an email when JAMA Cardiology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category